Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001783260 | SCV002023026 | pathogenic | Fanconi anemia complementation group D2 | 2019-05-20 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001885160 | SCV002133899 | pathogenic | Fanconi anemia | 2024-01-18 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg794*) in the FANCD2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCD2 are known to be pathogenic (PMID: 17436244). This variant is present in population databases (rs755350165, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with melanoma (PMID: 29625052). ClinVar contains an entry for this variant (Variation ID: 1322885). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV001783260 | SCV002792773 | likely pathogenic | Fanconi anemia complementation group D2 | 2022-02-17 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001783260 | SCV004196744 | likely pathogenic | Fanconi anemia complementation group D2 | 2023-07-26 | criteria provided, single submitter | clinical testing |